Understanding Mitchell Syndrome

Receiving a diagnosis of Mitchell Syndrome can feel overwhelming, especially because it is so rare and was only recently identified in 2020 ^[1][2]. As a parent, you are likely navigating a landscape of complex medical terms for a condition that many doctors may not have encountered before. You are not alone, and understanding the specific way this genetic change is thought to affect your child’s body is the first step in building an informed care plan.

What is Mitchell Syndrome?

Mitchell Syndrome (often abbreviated as MITCH) is an ultra-rare neurological disorder associated with a specific type of mutation in the ACOX1 gene ^[3][4]. While there are other disorders related to this gene, Mitchell Syndrome is unique because of how the mutation behaves.

It is important to distinguish Mitchell Syndrome from recessive ACOX1 deficiency (also known as pseudo-neonatal adrenoleukodystrophy).

• Recessive ACOX1 Deficiency: This occurs when a child inherits two mutated copies of the gene, severely impairing the body’s ability to use the ACOX1 enzyme ^[5][6]. Without adequate enzyme function, the body cannot effectively break down very-long-chain fatty acids (VLCFAs), which then build up ^[5].
• Mitchell Syndrome: This is associated with a gain-of-function mutation, usually a specific change called p.N237S (or p.Asn237Ser) ^[3]. In this case, your child likely has one normal copy of the gene and one mutated copy that is “overactive” ^[2][4]. Instead of a lack of activity, the mutation makes the enzyme hyper-stable and dysregulated ^[3].

Because the proposed biological mechanism is different, the treatments traditionally considered for recessive ACOX1 deficiency may not be effective or appropriate for Mitchell Syndrome ^[2][7].

How the Mutation is Thought to Affect Cells

The ACOX1 enzyme normally lives inside peroxisomes, which act as the “recycling centers” of the cell. In Mitchell Syndrome, laboratory models suggest the overactive enzyme creates a toxic environment through two main pathways:

1. Oxidative Stress: When the mutated ACOX1 enzyme works, it is thought to produce excess hydrogen peroxide as a byproduct ^[3]. This overproduction may lead to oxidative stress—a state where reactive molecules damage the cell’s internal structures ^[3][4].
2. Glial Damage: The nervous system relies on glia (supporting cells like Schwann cells and oligodendrocytes) to maintain the myelin sheath, which acts as insulation for nerves ^[3][2]. Researchers hypothesize that oxidative stress may damage these glial cells, leading to demyelination (the loss of that insulation) ^[3][8].

This proposed damage may cause the nerves in the brain (leukodystrophy) and the nerves in the rest of the body (polyneuropathy) to struggle to send signals correctly ^[8][1].

Common Clinical Features

Because Mitchell Syndrome affects both the central and peripheral nervous systems, it can involve multiple parts of the body. Based on the small number of reported cases, clinical features reported in the medical literature include:

• Neurological Changes: Episodic or progressive loss of myelin, which can lead to ataxia (problems with coordination and balance) and difficulty walking ^[8][4]. Some children may also experience seizures ^[4].
• Hearing and Vision: Sensorineural hearing loss and visual impairment have been noted in several cases ^[8][1].
• Skin Issues: Some children develop ichthyosiform erythroderma, which appears as red, scaly, or thickened skin ^[4][9]. This is also hypothesized to be linked to oxidative stress within the skin cells ^[4].

What is Known vs. What is Uncertain

Because this condition is so newly described, it is important to understand that the medical community is still learning.

• What is Known: The condition is tied to a specific genetic change, and its multi-system nature requires a team of specialists to monitor the brain, hearing, vision, and skin. We know that supportive therapies (like physical therapy and skin care) can improve comfort.
• What is Uncertain: The exact long-term progression for any individual child cannot be reliably predicted. Furthermore, there is currently no FDA-approved, universally established treatment protocol that halts or reverses the disease ^[2][4]. Investigational therapies, such as antioxidants, remain highly experimental and are based on limited case reports. Early genetic testing to confirm the p.N237S mutation is vital, as it ensures your child is being supported for Mitchell Syndrome and not misdiagnosed with a different peroxisomal disorder ^[3][4].